Omalizumab as a Desensitizing Agent and Treatment in Mastocytosis: A Review of the Literature and Case Report

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 3, 2014, Pages 266-270

  Sokol, Kristin C ^a   Ghazi, Aasia ^a   Kelly, Brent C ^a   Grant, J Andrew ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

ACE (angiotensin converting enzyme); Hymenoptera allergy; Mastocytosis; Omalizumab; Telangiectasia macularis eruptiva perstans; Venom immunotherapy

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALLERGEN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN E; OMALIZUMAB; TRYPTASE; VENOM; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

AGED; ALLERGIC REACTION; ANAPHYLAXIS; AORTA STENOSIS; AORTA VALVE REPLACEMENT; APITHERAPY; ARTICLE; BEE STING; BONE BIOPSY; CASE REPORT; COLLAPSE; COMORBIDITY; CORONARY ARTERY DISEASE; DESENSITIZATION; DRUG DOSE REDUCTION; FAINTNESS; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; LABORATORY TEST; MALE; SKIN BIOPSY; SKIN DEFECT; SYSTOLIC HEART MURMUR; TELANGIECTASIA MACULARIS ERUPTIVA PERSTANS; URTICARIA; URTICARIA PIGMENTOSA; WASP; IMMUNOLOGY; MASTOCYTOSIS; PROCEDURES;

AGED; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DESENSITIZATION, IMMUNOLOGIC; HUMANS; MALE; MASTOCYTOSIS;

EID: 84899745375     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.03.009     Document Type: Article

References (23)

1. Paraskevopoulos G., Sifnaios E., Christodoulopoulos K., Matopoulou F., Papakonstantis M., Sabaziotis D. Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy. Eur Ann Allergy Clin Immunol 2013, 45:52-55.
2. Rueff F., Dugas-Breit S., Przybilla B. Stinging Hymenoptera and mastocytosis. Curr Opin Allergy Clin Immunol 2009, 9:338-342.
3. Bonadonna P., Zanotti R., Muller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010, 10:347-353.
4. Carter M.C., Robyn J.A., Bressler P.B., Walker J.C., Shapiro G.G., Metcalfe D.D. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007, 119:1550-1551.
5. Kontou-Fili K., Filis C.I., Voulgari C., Panayiotidis P.G. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol 2010, 104:537-539.
6. Douglass J.A., Carroll K., Voskamp A., Bourke P., Wei A., O'Hehir R.E. Omalizumab is effective in treating systemic mastocytosis in nonatopic patient. Allergy 2010, 65:926-927.
7. Molderings G.J., Raithel M., Kratz F., Azemar M., Haenisch B., Harzer S., et al. Omalizumab treatment of systemic mast cell activation disease: experience from four cases. Intern Med 2011, 50:611-615.
8. Bell M.C., Jackson D.J. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 2012, 108:383-384.
9. Matito A., Blazquez-Goni C., Morgado J.M., Alvarez-Twose I., Mollejo M., Sanchez-Munoz L., et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol 2013, 111:425-426.
10. Gonzalez de Olano D., Alvarez-Twose I., Esteban-Lopez M.I., Sanchez-Munoz L., de Durana M.D., Vega A., et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008, 121:519-526.
11. Schulze J., Rose M., Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007, 62:963-974.
12. Galera C., Soohun N., Zankar N., Caimmi S., Gallen C., Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009, 19:225-229.
13. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008, 63:376-378.
14. Kontou-Fili K., Filis C.I. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009, 64:1384-1385.
15. Fricker M., Helbling A., Schwartz L., Muller U. Hymenoptera sting anaphylaxis and urticarial pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997, 100:11-15.
16. Niedoszytko M., de Monchy J., van Doormaal J.J., Jassem E., Oude Elberink J.N. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009, 64:1237-1245.
17. Monahan T.P., Petropolis A.A. Treatment of telangiectasia macularis eruptiva perstans with total skin electron beam radiation. Cutis 2003, 71:357.
18. Ellis D.L. Treatment of telangiectasia macularis eruptiva perstans with the 585-nm flashlamp-pumped dye laser. Dermatol Surg 1996, 22:33.
19. Sotiriou E., Apalla Z., Loannides D. Telangiectasia macularis eruptive perstans successfully treated with PUVA therapy. Photodermatol Photoimmunol Photomed 2010, 26:46-47.
20. Müller U.R. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007, 7:337-341.
21. Müller U.R., Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005, 115:606-610.
22. Golden D.B.K., Moffitt J., Nicklas R.A. Practice parameter: stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011, 127:852-854.e23.
23. Ruëff F., Przybilla B., Biló M.B., Müller U., Scheipl F., Aberer W., et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009, 124:1047-1054.